-
Something wrong with this record ?
Pediatric Chronic Heart Failure: Age-Specific Considerations of Medical Therapy
K. Koubský
Status minimal Language English Country Czech Republic
Document type Journal Article, Review
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
PubMed Central
from 2020
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Adrenergic beta-Antagonists therapeutic use MeSH
- Chronic Disease MeSH
- Child MeSH
- Angiotensin-Converting Enzyme Inhibitors therapeutic use MeSH
- Humans MeSH
- Heart Failure * drug therapy physiopathology MeSH
- Age Factors MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Chronic heart failure (CHF) is a rare entity in children but carries a burden of high mortality and morbidity. Medical treatment of pediatric CHF is largely based on guidelines for the adult population. In contrast to adults, evidence for the efficacy of medications in treating CHF in children is sparse. This may be due to the difficulty of conducting high-powered studies in children or to true differences in the mechanisms of CHF pathophysiology. Recent observations suggest that CHF in children differs from adults at the molecular and cellular levels. Different pathways are involved, leading to less fibrosis and hypertrophy than in adults, with potential implications for therapy. The main pathophysiological goals of medical treatment of pediatric CHF due to systemic left ventricular dysfunction are discussed in this review. These include preload and afterload optimization, diminishing cardiomyocyte apoptosis and necrosis as well as interstitial fibrosis, and optimizing myocardial oxygen consumption. The pediatric myocardium should be provided with optimal conditions to achieve its regenerative potential. The cornerstones of medical CHF therapy are angiotensin converting enzyme inhibitors (ACEI), beta blockers and mineralocorticoid receptor antagonists. There are potential benefits of tissue ACEI and ?1-selective beta blockers in children. Angiotensin receptor blockers are an alternative to ACEI and their slightly different mechanism of action may confer certain advantages and disadvantages. Diuretics are employed to achieve a euvolemic state. Digoxin is used more frequently in children than in adults. Promising new drugs already routinely used in adults include angiotensin receptor-neprilysin inhibitors and sodium-glucose contransporter 2 inhibitors. Key words: Pediatric heart failure, Heart failure with reduced ejection fraction (HFrEF), ACE inhibitor, Beta blocker, Digoxin.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25005524
- 003
- CZ-PrNML
- 005
- 20250312151250.0
- 007
- ta
- 008
- 250213s2024 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.935438 $2 doi
- 035 __
- $a (PubMed)39589305
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Koubský, K $u Children's Heart Centre, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic. karel.koubsky@fnmotol.cz
- 245 10
- $a Pediatric Chronic Heart Failure: Age-Specific Considerations of Medical Therapy / $c K. Koubský
- 520 9_
- $a Chronic heart failure (CHF) is a rare entity in children but carries a burden of high mortality and morbidity. Medical treatment of pediatric CHF is largely based on guidelines for the adult population. In contrast to adults, evidence for the efficacy of medications in treating CHF in children is sparse. This may be due to the difficulty of conducting high-powered studies in children or to true differences in the mechanisms of CHF pathophysiology. Recent observations suggest that CHF in children differs from adults at the molecular and cellular levels. Different pathways are involved, leading to less fibrosis and hypertrophy than in adults, with potential implications for therapy. The main pathophysiological goals of medical treatment of pediatric CHF due to systemic left ventricular dysfunction are discussed in this review. These include preload and afterload optimization, diminishing cardiomyocyte apoptosis and necrosis as well as interstitial fibrosis, and optimizing myocardial oxygen consumption. The pediatric myocardium should be provided with optimal conditions to achieve its regenerative potential. The cornerstones of medical CHF therapy are angiotensin converting enzyme inhibitors (ACEI), beta blockers and mineralocorticoid receptor antagonists. There are potential benefits of tissue ACEI and ?1-selective beta blockers in children. Angiotensin receptor blockers are an alternative to ACEI and their slightly different mechanism of action may confer certain advantages and disadvantages. Diuretics are employed to achieve a euvolemic state. Digoxin is used more frequently in children than in adults. Promising new drugs already routinely used in adults include angiotensin receptor-neprilysin inhibitors and sodium-glucose contransporter 2 inhibitors. Key words: Pediatric heart failure, Heart failure with reduced ejection fraction (HFrEF), ACE inhibitor, Beta blocker, Digoxin.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a srdeční selhání $x farmakoterapie $x patofyziologie $7 D006333
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a chronická nemoc $7 D002908
- 650 _2
- $a inhibitory ACE $x terapeutické užití $7 D000806
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a beta blokátory $x terapeutické užití $7 D000319
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 73, Suppl. 2 (2024), s. S597-S613
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39589305 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y - $z 0
- 990 __
- $a 20250213 $b ABA008
- 991 __
- $a 20250312151257 $b ABA008
- 999 __
- $a min $b bmc $g 2283560 $s 1242544
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 73 $c Suppl. 2 $d S597-S613 $e 20241129 $i 1802-9973 $m Physiological research $n Physiol Res $x MED00003824
- LZP __
- $a Pubmed-20250213